Ensysce Biosciences Receives $2 Million Financing to Advance Abuse- and Overdose-Resistant Analgesics

Ensysce Biosciences secured a $2 million convertible preferred stock financing under a prior commitment of up to $20 million. The capital will maintain the company's analgesic programs and support general corporate initiatives. The financing includes 100% warrant coverage with an 18-month and five-year term. The funding reflects investor confidence in Ensysce's differentiated analgesic programs, which have the potential to reinvent pain management.